# EDGAR Filing Document

**Accession Number:** 0001495222
**File Stem:** 0001213900-25-053284
**Filing Date:** 2025-6
**Character Count:** 6273
**Document Hash:** 5134603ae88abcd8ba760c17e300099d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-053284.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001213900-25-053284

**CONFORMED SUBMISSION TYPE**: 424B3

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Oxford Lane Capital Corp.
- **CENTRAL INDEX KEY:** 0001495222

**ORGANIZATION NAME:**
- **EIN:** 272859071
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 424B3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-283109
- **FILM NUMBER:** 251038841

**BUSINESS ADDRESS:**
- **STREET 1:** 8 SOUND SHORE DRIVE
- **STREET 2:** SUITE 255
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830
- **BUSINESS PHONE:** (203) 983-5275

**MAIL ADDRESS:**
- **STREET 1:** 8 SOUND SHORE DRIVE
- **STREET 2:** SUITE 255
- **CITY:** GREENWICH
- **STATE:** CT
- **ZIP:** 06830

?xml version='1.0' encoding='ASCII'?

**Filed pursuant to Rule 424(b)(3)**

**File No. 333-283109**

---

| | |
|:---|:---|
| **PROSPECTUS SUPPLEMENT**<br> **(To Prospectus dated November 8, 2024, as supplemented**<br> **by the Prospectus Supplement dated November 12, 2024,** <br> **by the Prospectus Supplement dated January 28, 2025 and** <br> **by the Prospectus Supplement dated May 21, 2025)** | **June 11, 2025** |

---

![](image_001.jpg)

**Oxford Lane Capital Corp.**

**$2,000,000,000 Common Stock**

This prospectus supplement contains information which amends, supplements and modifies certain information contained in the prospectus dated November 8, 2024 (the "Base Prospectus") as supplemented by the prospectus supplement dated November 12, 2024 (the "November 2024 Prospectus Supplement"), the prospectus supplement dated January 28, 2025 (the "January 2025 Prospectus Supplement") and the prospectus supplement dated May 21, 2025 (the "May 2025 Prospectus Supplement" and, together with the November 2024 Prospectus Supplement, the January 2025 Prospectus Supplement, this prospectus supplement and the Base Prospectus, the "Prospectus"), which relate to the sale of shares of common stock of Oxford Lane Capital Corp. (the "Company") in an "at-the-market" offering pursuant to an Amended and Restated Equity Distribution Agreement dated September 9, 2022, as amended pursuant to that certain Amendment No. 1, dated as of November 15, 2023, that certain Amendment No. 2, dated as of July 29, 2024, and that certain Amendment No. 3, dated as of November 12, 2024 (collectively, the "Amended Equity Distribution Agreement"), with Lucid Capital Markets, LLC and Ladenburg Thalmann & Co. Inc. (the "Distribution Agents"). The Company's investment adviser, Oxford Lane Management, LLC, has agreed to pay to the Distribution Agents, if necessary, a supplemental payment per share that will reflect the difference between the public offering price per share and the net proceeds per share received by the Company in this offering such that the net proceeds per share received by the Company (before expenses) are not below the Company's then current net asset value per share.

You should carefully read the entire Prospectus before investing in our common stock. **You should also review the information set forth under the "Risk Factors" section beginning on page 15 of the Base Prospectus and in our subsequent filings with the Securities and Exchange Commission that are incorporated by reference into the Prospectus, before investing.** 

The terms "Oxford Lane," the "Company," "we," "us" and "our" generally refer to Oxford Lane Capital Corp.

**PRIOR SALES PURSUANT TO THE "AT THE MARKET" OFFERING**

From November 12, 2024 to June 10, 2025, we sold a total of 127,496,226 shares of common stock pursuant to the "at-the-market" offering. The total amount of capital raised as a result of these sales of common stock was approximately $629.2 million and net proceeds were approximately $625.9 million, after deducting the sales agents' commissions and offering expenses.

**MAY 2025 FINANCIAL UPDATE**

On June 10, 2025, we announced the following net asset value ("NAV") estimate as of May 31, 2025.

● Management's unaudited estimate of the range of the NAV per share of our common stock as of May 31, 2025, is between $4.17 and $4.27. This estimate is not a comprehensive statement of our financial condition or results for the month ended May 31, 2025. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending June 30, 2025 may differ materially from this estimate, which is given only as of May 31, 2025.

● As of May 31, 2025, the Company had approximately 481.6 million shares of common stock issued and outstanding.

The fair value of the Company's portfolio investments may be materially impacted after May 31, 2025 by circumstances and events that are not yet known. To the extent the Company's portfolio investments are impacted by market volatility in the U.S. or worldwide, the Company may experience a material impact on its future net investment income, the fair value of its portfolio investments, its financial condition and the financial condition of its portfolio investments. Investing in our securities involves a number of significant risks. For a discussion of the additional risks applicable to an investment in our securities, please refer to the section titled "Risk Factors" in our prospectus and the section titled "Principal Risks" in our most recent annual report or semi-annual report, as applicable.

 

*The preliminary financial data included in this prospectus supplement has been prepared by, and is the responsibility of, Oxford Lane Capital Corp.'s management. PricewaterhouseCoopers LLP has not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers LLP does not express an opinion or any other form of assurance with respect thereto. The PricewaterhouseCoopers LLP report incorporated by reference relates to the Company's previously issued financial statements. It does not extend to the preliminary financial data and should not be read to do so.*